OSUR

Business Context and Reporting Period

Company: OraSure Technologies, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2009
Business Overview: OraSure develops, manufactures, and markets oral fluid diagnostic products (HIV, Hepatitis C, drugs of abuse) and cryosurgical systems for skin lesion removal. The company operates in one reportable segment, selling to clinical laboratories, hospitals, public health organizations, and retail markets globally.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 8% to $77.0 million, driven by a 21% increase in infectious disease testing sales ($46.1 million) and a 2% increase in cryosurgical systems sales. This was partially offset by a 14% decline in substance abuse testing revenues due to economic conditions and competition.
• Profitability Improvement: The net loss narrowed significantly from $31.3 million in 2008 to $7.8 million in 2009. The 2008 loss included a $26.0 million income tax charge to establish a full valuation allowance on deferred tax assets, which did not recur in 2009.
• Unusual Items:
  • Patent Litigation Settlement: A $3.0 million payment was made to settle a patent infringement lawsuit with Inverness Medical. $1.5 million was expensed immediately; the remainder was capitalized as prepaid royalties.
  • Impairment Charge: A $3.0 million non-cash impairment charge was recorded for HCV patent rights due to the inability to penetrate international markets with a third-party test.
• Operational Shift: The company transitioned to a direct sales model for the U.S. hospital market in January 2009 following the termination of a distribution agreement with Abbott Laboratories, resulting in higher average selling prices and improved gross margins.

Guidance, Outlook, and Risks

• Product Pipeline:
  • OraQuick HCV: Received CE mark approval for Europe in late 2009. FDA PMA approval for the U.S. is pending additional clinical studies expected to complete in the first half of 2010.
  • OraQuick HIV OTC: Clinical studies are ongoing. The company expects to submit an FDA application after completing additional clinical work in 2010 and 2011.
  • Substance Abuse: Entered a commercialization agreement with Roche Diagnostics in January 2010 for fully-automated oral fluid drug assays.
• Management Commentary: Management expects 2010 R&D and sales/marketing expenses to increase due to clinical trials and new product launches. They anticipate continued decline in OraSure collection device sales as customers shift to the OraQuick rapid test.
• Key Risks:
  • Regulatory: Delays or failure to obtain FDA approval for the OTC HIV test or HCV test could significantly reduce future revenues.
  • Supply Chain: Reliance on sole-source suppliers for critical components (HIV antigen, nitrocellulose) creates supply disruption risks.
  • Competition: Intense competition in HIV testing and increasing pressure from "home-brew" assays in the drug testing market.
  • Economic: Continued economic downturn may impact workplace drug testing demand and government funding for public health initiatives.

Investor Verification Checklist

• Regulatory Milestones: Verify the timeline and success of the additional clinical studies required for FDA approval of the OraQuick HCV test and the OraQuick HIV OTC test.
• Patent Settlement Impact: Confirm the amortization schedule of the $1.5 million prepaid royalties from the Inverness settlement and monitor for any future litigation risks.
• Substance Abuse Recovery: Assess the impact of the new Roche Diagnostics partnership on reversing the decline in Intercept drug testing revenues.
• Deferred Tax Assets: Review the company's ability to generate future taxable income to utilize the $54.1 million in Net Operating Loss (NOL) carryforwards, given the full valuation allowance currently in place.
• Customer Concentration: Monitor sales to Quest Diagnostics, which accounted for 9% of total revenues in 2009.